Feed PURE
PU

PURE Bioscience, Inc. PURE · OTC

$0.07 +5.90% (+$0.00)

Summary

27 / 100 · Bulios Score

What speaks for it

  • The share price is below the Bulios Fair Price.
  • The price moves less than the market (beta 0.23).

What to watch

  • The company made a loss over the last 12 months.
  • Repaying its net debt would take 29.8 years of operating profit.
  • It passes only 3 of the 9 points of the Piotroski financial health test.

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Score in detail

Price

Is it expensive?

Looks cheap
Bulios Fair Price
Current price $0.072

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

The company made a loss over the last 12 months, so there is no profit to set the price against.

Valuation in detail

Is it growing?

Slowly

Revenue (USD)

Diluted EPS (USD)

Revenue fell by 20% a year over 5 years. Over the last 3 years it grew by 5.9% a year.

Growth in detail

Does it make money?

Poorly

Over the last 12 months it made a loss of $2.21M.

Profitability in detail

Is it financially healthy?

Debt is a burden

Over the last 12 months it spent more cash than it brought in. Its debt is larger than its cash.

Financial health in detail

Does it pay a dividend?

No

It pays no dividend.

Dividends in detail

What do analysts expect?

Neutral

No analyst has published a price target.

0.0% of the analysts recommend buying.

Analysts in detail

What does it earn on?

Fiscal year 2025

By product

By region

The company reports no revenue by region.

PURE Hard Surface brings in 91% of revenue. SIL VERION grew fastest, by 55% a year.

Segments in detail

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.